

May 9, 2017

The Manager - Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

The Manager - Listing
BSE Limited
Corporate Relationship Dept., 1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

Dear Sir(s),

Outcome of the Board Meeting held on Tuesday, May 9, 2017

Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2017

We wish to inform that the Board of Directors of the company at the meeting held on Tuesday, May 9, 2017, considered and approved the Audited Financial Results for the quarter and year ended March 31, 2017. The said Audited Financial Results together with the Report of the Statutory Auditors dated May 9, 2017 are sent herewith.

We also confirm that the Auditor's Report is with unmodified opinion in respect of the Audited Financial Results of the Company for the year ended March 31, 2017.

We request you to kindly take the above on records.

For **AstraZeneca Pharma India Limited**



Pratap Rudra
Company Secretary & Legal Counsel

Part I	Rs in lakhs (except in respect of SI No.16)					
Statement of unaudited financial results for the quarter and audited financial results for year ended 31 March 2017						
SI No.	Particulars	3 months ended 31/03/2017 (Unaudited)	3 months ended 31/12/2016 (Unaudited)	3 months ended 31/03/2016 (Unaudited)	Year ended 31/03/2017 (Audited)	Previous year ended 31/03/2016 (Audited)
1	Income from operations					
	a) Net sales/ income from operations (net of excise duty)	11,095.22	14,112.34	13,351.48	52,631.16	52,645.98
	b) Other operating income	62.56	916.26	2,530.56	1,325.85	3,727.25
	Total income from operations (net)	11,157.78	15,028.60	15,882.04	53,957.01	56,373.23
2	Expenses					
	(a) Cost of materials consumed	530.38	244.49	868.74	1,400.42	3,475.85
	(b) Purchase of stock-in-trade	2,808.14	3,567.46	4,821.39	14,215.53	15,888.71
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	431.76	893.09	(521.24)	1,750.87	541.52
	(d) Employee benefits expense	3,607.34	3,811.90	5,086.01	16,347.64	16,934.52
	(e) Depreciation and amortisation expense	367.50	401.92	423.71	1,582.60	1,742.64
	(f) Selling, marketing and distribution	840.76	1,861.29	2,234.57	5,405.64	7,194.29
	(g) Other expenses	3,414.20	3,156.25	3,071.95	11,898.12	10,696.60
	Total expenses	12,000.08	13,936.40	15,985.13	52,600.82	56,474.13
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	(842.30)	1,092.20	(103.09)	1,356.19	(100.90)
4	Other income	643.17	983.27	209.29	1,964.29	677.27
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	(199.13)	2,075.47	106.20	3,320.48	576.37
6	Finance costs	-	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	(199.13)	2,075.47	106.20	3,320.48	576.37
8	Exceptional items	-	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	(199.13)	2,075.47	106.20	3,320.48	576.37
10	Tax expense	88.41	479.18	50.47	876.26	50.47
11	Net profit/(loss) from ordinary activities after tax (9-10)	(287.54)	1,596.29	55.73	2,444.22	525.90
12	Extraordinary item	-	-	-	-	-
13	Net profit/(loss) for the period (11-12)	(287.54)	1,596.29	55.73	2,444.22	525.90
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year				17,545.66	15,101.43
16	Basic and diluted earnings per share (of Rs 2 each) [not annualised]	(1.15)	6.39	0.22	9.78	2.10

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 9th May 2017.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. 'Others' comprises of service income pertaining to clinical trials.
- AstraZeneca Pharmaceuticals AB, Sweden, the promoter of the Company vide its letter dated 1 March 2014, had proposed voluntary delisting of equity shares from stock exchanges ('Delisting Proposal'). The Board of Directors of the Company at their meeting held on 15 March 2014, had accorded approval for the Delisting Proposal. Further, the Delisting Proposal has been approved by the requisite majority of shareholders of the Company as required under Regulation 8 of SEBI (Delisting of Equity Shares) Regulations, 2009. Securities Exchange Board of India (SEBI) in its Order dated 24 June 2014 has issued directions to Bombay Stock Exchange and National Stock Exchange to closely monitor the entire delisting process of the Company and the Company shall finally purchase shares from the public shareholders in the delisting offer only after seeking approval from Bombay Stock Exchange and National Stock Exchange. The Company has received in-principle approval of National Stock Exchange and Bombay Stock Exchange, for voluntary delisting of equity shares from the said exchanges. A writ petition had been filed by two shareholders of the Company before the Honourable High Court of Judicature at Bombay ("the Court"), seeking inter-alia an order from the Court, restraining the Company and AstraZeneca Pharmaceuticals AB, Sweden ("AZPAB") from implementing the Delisting Proposal. The Court which heard the petition on 8 October 2014 has disposed off the same, with the directions that the Petitioners as well as the Company and AZPAB are at liberty to prefer appeal against SEBI Order dated 24 June 2014, to the Securities Appellate Tribunal (SAT), within six weeks and until the SAT hears and disposes of the Petitioners' appeal, the Company and AZPAB shall not take any further steps in the process of delisting of equity shares of the Company. The SAT was requested to hear and decide the appeals as expeditiously as possible and preferably by 28 February 2015. Further, an appeal has also been filed by two shareholders of the Company before the SAT, Mumbai, against part of SEBI's Order dated 24 June 2014, in relation to Delisting Proposal. The case was posted for hearing on multiple dates during the year ended 31 March 2015. At the hearing held on 5 May 2015, the SAT posted the matter to be heard on 9 July 2015 which was subsequently rescheduled for hearing on 11 August 2015. In the final hearing held on 11 September 2015, the SAT has disposed off the appeal directing SEBI to complete the investigation within a period of six months from date of its order and pass appropriate order on merits. The SAT has further directed the Company and the Promoter not to proceed with the delisting of equity shares till the completion of investigation and passing of the above mentioned order on merits by SEBI. Also the SAT has directed the Company and the Promoters that if the order passed by SEBI on merits is adverse to the appellants, then the said order shall not be given effect to from the date of passing the said order till it is communicated to the appellants and four weeks thereafter.
- The figures for the quarter ended 31 March 2017 and the corresponding quarter ended in the previous year as reported in this financial result is the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also figures upto the third quarter of the relevant financial year were only reviewed and not subjected to audit. The statutory auditors have issued an unqualified audit report for the year ended March 31 2017. The audit report has been filed with the stock exchange and is also available on the Company's website.
- Previous period figures have been reclassified, as considered necessary, to conform with current period presentation, where applicable.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjay Murdeshwar
Managing Director

Place: Bengaluru
Date: May 9, 2017

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Segment wise revenue, results and capital employed

(Rs in lakhs)

Sl.no.	Particulars	3 months ended 31/03/2017 (Unaudited)	3 months ended 31/12/2016 (Unaudited)	3 months ended 31/03/2016 (Unaudited)	Year ended 31/03/2017 (Audited)	Previous year ended 31/03/2016 (Audited)
1	Segment revenue					
	(a) Healthcare	10,714.83	14,276.48	15,438.15	51,793.17	55,402.82
	(b) Others	442.95	752.12	443.89	2,163.84	970.41
	Net sales/income from operations	11,157.78	15,028.60	15,882.04	53,957.01	56,373.23
2	Segment results					
	Profit/(Loss) before tax and interest					
	(a) Healthcare	(854.62)	1,080.71	(113.27)	1,311.25	(135.16)
	(b) Others	12.32	11.49	10.18	44.94	34.26
	Total	(842.30)	1,092.20	(103.09)	1,356.19	(100.90)
	Add: Other income	643.17	983.27	209.29	1,964.29	677.27
	Total Profit/(Loss) before tax	(199.13)	2,075.47	106.20	3,320.48	576.37
3	Capital employed					
	(a) Healthcare	5,928.36	6,120.00	6,791.87	5,928.36	6,791.87
	(b) Others	(971.99)	(1,157.48)	(165.94)	(971.99)	(165.94)
	(c) Unallocated	13,089.29	13,370.69	8,975.50	13,089.29	8,975.50
	Total	18,045.66	18,333.21	15,601.43	18,045.66	15,601.43

Notes :

- 1 Certain assets and liabilities not identifiable with individual business segments are used interchangeably between the business segments. Hence, such assets and liabilities have not been allocated to any segment.

AstraZeneca Pharma India Limited
Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Bangalore 560 045

Statement of assets and liabilities

(Rs in lakhs)

Sl.No.	Particulars	As at 31 March 2017 (Audited)	As at 31 March 2016 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	500.00	500.00
	(b) Reserves and Surplus	17,545.66	15,101.43
	(c) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	18,045.66	15,601.43
2	Share application money pending allotment	-	-
3	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	151.49	126.69
	(d) Long-term provisions	1,090.53	1,165.70
	Sub-total - Non-current liabilities	1,242.02	1,292.39
4	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	3,577.04	9,462.84
	(c) Other current liabilities	12,936.36	12,108.48
	(d) Short-term provisions	1,973.41	1,833.25
	Sub-total - Current liabilities	18,486.81	23,404.57
	TOTAL - EQUITY AND LIABILITIES	37,774.49	40,298.39
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	9,164.88	10,366.82
	(b) Non-current investments	-	0.05
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	3,272.15	3,163.81
	(e) Other non-current assets	60.55	60.55
	Sub-total - Non-current assets	12,497.58	13,591.23
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	5,771.77	7,672.96
	(c) Trade receivables	4,360.32	8,314.32
	(d) Cash and bank balances	11,496.19	7,683.18
	(e) Short-term loans and advances	2,216.99	2,763.69
	(f) Other current assets	1,431.64	273.01
	Sub-total - Current assets	25,276.91	26,707.16
	TOTAL - ASSETS	37,774.49	40,298.39